2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

4:30PM-6:00PM: Abstract Number: 1029

Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of Th17-Cell Mediated Autoimmune Arthritis

Rheumatoid Arthritis – Animal Models I

4:30PM-6:00PM: Abstract Number: 1031

Glucocorticoid Receptor Dimerization in Stromal Cells Modulates Macrophage Polarization during Serum Transfer-Induced Arthritis

Rheumatoid Arthritis – Animal Models I

4:30PM-6:00PM: Abstract Number: 1004

Herpes Zoster Virus Infection in Patients Treated with Biological Therapies (BIOBADASAR)

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1049

High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design

4:30PM-6:00PM: Abstract Number: 1006

Immune Complex-Mediated TLR8 Activation Shifts Neutrophils from Phagocytosis to Netosis through Furin-Dependent Shedding of Fcgriia

Innate Immunity and Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1007

Interferon Regulatory Factor 1 Is the Key Driver of Inflammasome Activity in Systemic Lupus Erythematosus

Innate Immunity and Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1014

Juvenile Dermatomyositis: What Comes Next?

Muscle Biology, Myositis and Myopathies

4:30PM-6:00PM: Abstract Number: 1052

Longitudinal Patterns in SLE Response to Standard of Care Therapy: Implications for SLE Clinical Trial Design

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design

4:30PM-6:00PM: Abstract Number: 1021

Maintaining Sufficient Serum Vitamin D Levels over 2 Years Is Associated with Reduced Knee Structural and Symptomatic Changes in Patients with Knee Osteoarthritis

Osteoarthritis – Clinical Aspects I: Epidemiology and Progression

4:30PM-6:00PM: Abstract Number: 1034

Microrna-146a Controls Local Bone Destruction By Regulating Fibroblast Induced Osteoclastogenesis in Inflammatory Arthritis

Rheumatoid Arthritis – Animal Models I

4:30PM-6:00PM: Abstract Number: 1056

Mind-Body Skills Training and Supportive Counseling for Depression in SLE: Positive Effects in a Randomized Controlled Trial

ARHP II: Healthcare Disparities and and Psychosocial Impact on Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 1026

Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 1047

Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability

Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design

4:30PM-6:00PM: Abstract Number: 1027

Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 987

Pesticide Exposure and Risk of Rheumatoid Arthritis in Licensed Male Pesticide Applicators in the Agricultural Health Study

Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].